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Abstract Background Hypoxia resulting from ascent to high-altitude or pathological states at
sea level is known to increase platelet reactivity. Previous work from our group has
suggested that this may be adenosine diphosphate (ADP)-speciﬁc. Given the clinical
importance of drugs targeting ADP pathways, research into the impact of hypoxia on
platelet ADP pathways is highly important.
Methods Optimul aggregometry was performed on plasma from 29 lowland residents
ascending to 4,700m, allowing systematic assessment of platelet reactivity in response to
several platelet agonists. Aggregometry was also performed in response to ADP in the
presence of inhibitors of the two main ADP receptors, P2Y1 and P2Y12 (MRS2500 and
cangrelor, respectively). Phosphorylation of vasodilator-stimulated phosphoprotein
(VASP), a key determinant of platelet aggregation, was analysed using the VASPFix assay.
Results Hypobaric hypoxia signiﬁcantly reduced the ability of a ﬁxed concentration of
cangrelor to inhibit ADP-induced aggregation and increased basal VASP phosphoryla-
tion. However, in the absence of P2Y receptor inhibitors, we did not ﬁnd evidence of
increased platelet sensitivity to any of the agonists tested and found reduced sensitivity
to thrombin receptor-activating peptide-6 amide.
Conclusion Our results provide evidence of increased P2Y1 receptor activity at high
altitude and suggest down-regulation of the P2Y12 pathway through increased VASP
phosphorylation. These changes in ADP pathway activity are of potential therapeutic
signiﬁcance to high-altitude sojourners and hypoxic sea level patients prescribed
platelet inhibitors and warrant further investigation.
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Introduction
Acutehypobarichypoxia, suchas that inducedbyascent tohigh
altitude, has long been considered to produce a thrombogenic
phenotype.1 Consistent with this, epidemiological studies
report a markedly increased risk of strokes at high altitude:
up to 30 times that at sea level.2 Furthermore, these events are
reported to occur in younger patients with fewer cardiovascu-
lar risk factors.3Although some studies examining the effect of
acute hypoxia on coagulation have reported minimal changes
in coagulation, they were investigating the ‘economy class
syndrome’ and thus exposure to hypoxia was brief.4,5 On the
contrary, studies examining a longer exposure to hypoxia have
demonstrated a hypercoagulable state.6–8
Platelets are key to haemostasis9,10 and appear to have an
important role in the hypercoagulable state induced by hypox-
ia: expressionof solubleP-selectin, an invivoplatelet activation
marker,was shown to be increased 2.5-fold after ascent to high
altitude.11 Furthermore, hypoxia has recently been shown to
signiﬁcantly alter the platelet proteome, including up-regula-
tion of calpain small subunit 1.12 Calpains are calcium-depen-
dent proteases involved in various physiological processes
including platelet activation.13 The same study also found
increased intracellular calcium concentration in hypoxic
platelets12 which is a common downstream effect of platelet
activation by several agonists, including adenosine diphos-
phate (ADP).10
Recent work from our group has demonstrated a hyperco-
agulable state in 63 subjects participating in a controlled, non-
exertional sojourn to 5,300 m.6 Multiplate aggregation assays
using ﬁxed doses of several platelet activators at this altitude
suggested that hypoxia-induced platelet hyper-reactivity is
speciﬁc to ADP as responses to thrombin receptor-activating
peptide (TRAP) and collagenwere not altered.6 It is known that
ADPacts on twopro-aggregatory pathways, via P2Y1 and P2Y12
receptors,14 and in light of our previous ﬁndings we aimed to
further investigate these pathways. P2Y12 inhibitors arewidely
used anti-platelet medications, and effects of hypoxia on their
efﬁcacy are of high clinical relevance. This is particularly
important given the increasing number of older sojourners to
high altitude, who may have cardiovascular co-morbidities.15
Our study is the ﬁrst to our knowledge to investigate the
effect of hypoxia on the major platelet activation pathways
with full concentration–response curves. Optimul aggreg-
ometry is a recently developed assay which applies the
principles of light-transmission aggregometry to a 96-well
format, with platelet agonists lyophilised in each well.16 This
assay requires signiﬁcantly less plasma volume than tradi-
tional aggregometry, thus facilitating systematic assessment
of platelet aggregation in response to several agonists. Ex
vivo use of ADP receptor inhibitors also permitted further
detailed study of the purinergic pathways in a group of
healthy, lowland volunteers ascending to 4,700 m.
Methods
Data were collected from 29 participants before and during
the APEX 5 Expedition. All participants had no known
cardiovascular or respiratory conditions and no pre-existing
coagulopathy. Participants were asked to refrain from
alcohol and anti-platelet medications during the week prior
to sampling. This study was approved by the ACCORD
Research Ethics Committee (17-HV-030) and all participants
gave informed consent as per the Declaration of Helsinki.
Reagents were supplied by Sigma-Aldrich (Irvine, United
Kingdom) unless otherwise speciﬁed.
Ascent Proﬁle and Sample Collection
Participants were resident at< 250m above sea level and had
not travelled to high altitude (> 2,500m) in the2monthsprior
to the study. The ascent proﬁle and study timeline are sum-
marised in►Fig. 1. We chose to perform aggregometry assays
on day 6 (one day following ascent to 4,700 m to examine
effects of sub-acute hypoxia) and day 11 (the time point we
had previously observed changes in Multiplate aggregation
with ADP6). Venepuncture was performed using 21G needles
(Williams Medical, Rhymney, United Kingdom) into citrated
tubes. Platelet-rich plasma (PRP) was prepared by centrifuga-
tion of whole blood at 175 g for 15minutes (EBA 280,
Hettich, Tuttlingen, Germany). Platelet-poor plasma (PPP)
was generated by further centrifugation at 3,624 g for
2minutes. Peripheral oxygen saturation (SpO2) wasmeasured
using a pulse oximeter (SM-100, Santamedical, Tustin, United
States) at baseline and every day of the expedition.
Optimul Aggregometry
Modiﬁed optimul aggregometry plates were prepared as
previously described by Chan and Warner.16 In brief, pre-
diluted platelet agonists were added to individual wells of a
gelatin-coated 96-well plate and the plates were lyophilised.
Plates were vacuum-sealed and protected from light before
use. Each 96-well plate contained lyophilised concentration
ranges of arachidonic acid (0.03–1mM), ADP (0.005–40 µM),
Fig. 1 Ascent proﬁle. Baseline testing was performed in April 2017,
2 months prior to the expedition. Subjects landed in La Paz (3,700 m)
where they spent four nights before ascending to Huayna Potosi Base
Camp (4,700 m) by bus on day 5 where they stayed for the remainder
of the study. Optimul aggregometry, VASPFix and full blood count
samples were collected at baseline and on day 11. On day 6, only
optimul aggregometry was performed.
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collagen (0.01–40 µg/mL), epinephrine (0.0004–10 µM),
TRAP-6 amide (0.03–40 µM), and U46619 (thromboxane
mimetic, 0.005–40µM).
PRP was aliquoted and incubated for 30minutes (at 37°C)
alone or in the presence of the P2Y1 inhibitor MRS2500 (1 µM,
Tocris Bioscience, Bristol, UnitedKingdom) or the P2Y12 inhibi-
tor cangrelor (100nM, The Medicines Company, New Jersey,
United States). After incubation, 40 µL of PRP (plus or minus
inhibitor)wasquicklyadded towells containing the lyophilised
platelet agonists. PPP was added to four agonist-free wells to
provide a signal equivalent to 100% aggregation. PRP was also
added to agonist-free wells and wells containing vehicle alone
as a 0% aggregation control. Plates were then placed on a
thermal shaker (BioShake iQ, QInstruments, Jena, Germany)
for 5minutes (37°C, 1,200 revolutions per minute).
Light absorbance was read at 595 nm in a 96-well plate
reader (SPECTROstar Nano, BMG LABTECH, Aylesbury,
United Kingdom).
Percentage aggregation was calculated using absorbance
values for PPP (100%) and PRP (0%) in agonist-free wells as
referencevalues.Avisual inspectionofconcentration–response
curves was conducted to remove any clearly erroneous curves
(deviating from a sigmoid shape). Data were also removed if
they showed no response, with response deﬁned as greater
than 30% aggregation in response to two doses of agonist.
Vasodilator-Stimulated Phosphoprotein
Phosphorylation
Vasodilator-stimulated phosphoprotein (VASP) is a platelet
proteinwhose phosphorylation is modulated by cyclic adeno-
sine monophosphate (cAMP).17 cAMP production is inhibited
by the action of Gαi on adenylate cyclase secondary to activa-
tion of P2Y12 receptors.
18 The degree of VASP phosphorylation
can thus be used as a marker of P2Y12 activity.
19 The VASPFix
assay20 was used to quantify VASP phosphorylation.
Aliquots of PRP were incubated for 6minutes in one of
three conditions: phosphate-buffered saline (PBS), a prosta-
cyclin analogue iloprost (1 nM), or ADP (5 µM)þ iloprost
(1 nM) and mixed in a 1:5 ratio with VASPFix (Platelet
Solutions Ltd., Nottingham, United Kingdom), vortexed,
and snap frozen on dry ice. Samples from high altitude
were transported to the United Kingdom for analysis on
dry ice by a specialist company.
Flow cytometry was performed and the median ﬂuores-
cein isothiocyanate ﬂuorescence (mf) recorded for each
condition. Iloprost induces maximal VASP phosphorylation
with PBS acting as a negative control.
If iloprost did not induce phosphorylation (i.e., if mf (ilo-
prost)<mf (saline)), it was assumed that therewas a technical
failureand thesesamples removed fromtheanalysis. Similarly,
if mf (iloprostþADP) was greater than mf (iloprost), the
sample was also removed from analysis.
Full Blood Count
Three millilitres of blood were collected into an ethylenedia-
minetetraacetic acid blood tube (Sarstedt Ltd., Leicester, United
Kingdom) and samples analysed within 24 hours by clinical
haematology laboratories (NHS Lothian Laboratories, Edin-
burgh, United Kingdom, and SELADIS, Universidad Mayor de
San Andrés, La Paz, Bolivia).
Statistics
Optimul aggregometry data were ﬁt to Eq. (1) by least
squares, non-linear regression using the scipy.optimize li-
brary (for Python 2.7.2).
Eq. (1): Agonist-response equationwhere y is the percentage
aggregation,x is log[agonist], EC50 theconcentrationresulting in
half maximal aggregation, Top/Bottom the maximum/mini-
mum aggregation and the Hill Slope the steepness of the curve.
For studies examining the dose–response curve of cangrelor,
IC50 replaces EC50.
The concentration resulting in half-maximal aggregation
(EC50) was used to compare curves from each time point.
For comparisons between ADP concentration–response
curves in the presence of a ﬁxed antagonist, maximum
response (Rmax) to ADP was also calculated.
Outlier identiﬁcation was based on difference of ﬁts
analysis.21 The effect of each point on EC50 (ΔEC50) and Hill
Slope (ΔHill) was calculated by iterative removal of points
and reﬁtting the curves. ΔEC50 and ΔHill values were
reviewed for comparable data (all points in all concentra-
tion–response curves for one agonist at one time point) and
any points falling out with two standard deviations (ΔEC50)
or four standard deviations (ΔHill) were considered outliers.
Additionally, for concentration–response curves in the pres-
ence of inhibitors, if the ﬁnal point was less than 75% of the
point preceding it, it toowas considered an outlier, to ensure
validity of the Rmax parameter.
Wherever possible, paired statistics were used; however,
the optimul aggregometry data were unpaired. For paired
comparisons of two time points, paired Student’s t-tests
were performed using the scipy.stats library.22 For paired
data compared over three time points (SpO2), a one-way
repeated-measure analysis of variance (ANOVA) was con-
ducted with a Tukey’s HSD post hoc test using Prism 5.0
(GraphPad, La Jolla, California, United States). For optimul
aggregometry data, comparisons between three time points
were analysed using one-way ANOVA with Tukey’s HSD post
hoc test using R3.4.2.23Whenevermultiple comparisonswere
made, between multiple agonists or conditions, p-values
reportedwere adjusted using a Bonferroni correction. Statisti-
cal signiﬁcance was set as 0.05.
Results
Baseline characteristics of subjects are summarised
in ►Table 1.
All but one subject completed the study, and data have
been included until dropout for unpaired analyses. The
sojourn at high altitude induced a marked hypoxaemia
(►Fig. 2A), which was slightly more pronounced on day 11
than day 6. Platelet counts were also signiﬁcantly elevated by
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hypoxia (►Fig. 2B). Haemoglobin, haematocrit andwhite cell
count data are provided in ►Supplementary Table S1 (avail-
able in the online version).
Hypoxic Platelets are Less Sensitive to TRAP-6 Amide
The effect of hypoxia on various platelet agonists was com-
pared between baseline, day 6 and day 11. No platelet
activation pathways were found to be sensitised by hypoxia;
however, platelets became less sensitive to TRAP-6 amide
(►Fig. 3E,►Table 2, p< 0.01). This effect was only present on
day 11.
Hypoxia Modulates Purinergic Signalling
In the presence of 1 µM P2Y1 inhibitor MRS2500, both EC50
and Rmax were unchanged by hypoxia (►Fig. 4A, ►Table 2).
Likewise, in the presence of 100 nM P2Y12 inhibitor cangre-
lor, EC50 remained unchanged after 11 days of hypoxia.While
EC50 remained unchanged at altitude, Rmax was markedly
increased on both days 6 and 11 compared with baseline
(►Fig. 4B, ►Table 2, p< 0.01).
Hypoxia Modulates Basal VASP Phosphorylation in
Platelets
Compared with baseline, after 11 days at high altitude there
was a highly signiﬁcant increased mf in the PBS-treated
samples (►Fig. 5A). There were no differences between base-
line and day 11 in other conditions (►Fig. 5A). There was a
marked reduction in the mf percentage increase induced by
iloprost at high altitude (►Fig. 5B), but no change in mf
reduction induced by the addition of ADP (►Fig. 5C).
Discussion
There is a growing body of evidence that hypoxia induces
hyper-reactivity in platelets, a phenomenon important to
both altitude physiology and sea-level pathophysiology. We
found that hypoxia increases maximal aggregation to ADP in
the presence of cangrelor and down-regulates platelet sen-
sitivity to TRAP-6 amide. However, we did not demonstrate
sensitisation to any of the platelet activators tested. Finally,
and more strikingly, we have demonstrated modulation of
basal VASP phosphorylation, a key step in the P2Y12 signal-
ling pathway.
Our results contrast with a previous study from our group
which reported increased platelet sensitivity to ADP.6 Our
previous ﬁndings were based on Multiplate analysis and dis-
crepancies could be related to the impact of platelet count on
the twodifferent assays:Multiplate ismoresensitive toplatelet
count than optimul aggregometry.24,25 This, however, would
not explain why our previous ﬁndings were speciﬁc to ADP.
Perhapsmorelikely is thatdifferences relate totheparameterof
platelet function that was tested. Multiplate is based on
electrical-impedance aggregometry measured in real-time
over 6minutes, with the area under the impedance time curve
as theﬁnal outcome.26This outcome is therefore dependent on
both the ﬁnal amplitude of the response and the rate at which
this is reached. Optimul aggregometry, however, is based on
onemeasurement at 5minutes. Conceivably, differences in the
ADP sensitivity could be time dependent, given the time
sensitivity of phosphorylation27 and changes in purinergic
receptor expression28 induced by ADP stimulation.
While we have not resolved the uncertainty surrounding
ADP sensitivity, our study did reveal interesting changes in
purinergic signalling. The Rmax induced by ADP in the presence
of 100 nM cangrelor was signiﬁcantly higher at altitude
(►Fig. 4B, ►Table 2). This could be due to increased P2Y1
receptor activity. An increase in P2Y1 activity may imply a
difference in receptor expression or modulation of receptor
activity since G-protein-coupled receptor activity can be regu-
latedbymultiplemechanisms.29 IncreasedP2Y1activitywould
provide an interesting link to the proteomic data of Tyagi et al
whodescribed increased calpain expressionand activity in rats
exposed to hypoxia for 6 hours,12 since a downstream conse-
quence of P2Y1 activation is increased intracellular calcium.
30
Well-controlled, high-altitude expeditions are excellent
models of acute hypoxia31 and their ﬁndings are often relevant
to hypoxic patients at sea level. In this regard, patients with
chronic hypoxic diseases such as chronic obstructive pulmo-
nary disease and obstructive sleep apnoea (OSA) have an
increased risk of thrombotic events such as myocardial infarc-
tion and stroke.32,33 Furthermore, these conditions are also
associatedwith increased platelet reactivity, which in the case
of OSA is reversed on correction of hypoxia.34–36However, the
Table 1 Baseline characteristics
Characteristic APEX 5 cohort
Sex (male/female) 9/20
Mean BMI (range) 22.3 (17.6–28.8)
Mean age (range) 20.7 (18–26)
Note: Bodymass index (BMI) has units kg/m2, and age ismeasured in years.
Fig. 2 Platelet counts and oxygen saturations. (A) Oxygen saturation
was measured at baseline and on day 6 and day 11 of the expedition.
Data points are represented as semi-translucent circles, with sum-
mary box plots superimposed. Data were analysed by a one-way
repeated-measure analysis of variance (ANOVA) followed by a Tukey’s
HSD test. (B) Platelet count was measured at baseline and on day 11 of
the expedition. Data points are represented as semi-translucent
circles, with summary box plots superimposed. Data were analysed by
paired Student’s t-test. p< 0.001, p< 0.05.
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Table 2 Summary results of optimul aggregometry data
EC50 values
Baseline Day 6 Day 11
AA –3.695 (0.053) –3.696 (0.039) –3.715 (0.064)
ADP –5.990 (0.096) –6.037 (0.122) –5.912 (0.078)
Collagen –6.776 (0.111) –7.009 (0.107) –6.853 (0.088)
Epinephrine –6.339 (0.194) –6.805 (0.144) –6.584 (0.140)
TRAP-6 amide –6.314 (0.105) –6.221 (0.064) –5.759 (0.084)a
U46619 –6.979 (0.122) –6.652 (0.099) –6.545 (0.122)
ADPþMRS2500 –5.280 (0.082) –5.222 (0.063) –5.244 (0.064)
ADPþ Cangrelor –5.186 (0.062) –5.318 (0.068) –5.335 (0.079)
Rmax values
ADPþMRS2500 95.230 (2.835) 100.413 (2.159) 96.638 (2.788)
ADPþ Cangrelor 80.005 (4.177) 97.927 (2.557)a 97.186 (2.398)a
Abbreviations: AA, arachidonic acid; ADP, adenosine diphosphate; PRP, platelet-rich plasma; TRAP, thrombin receptor-activating peptide.
Note: Dose–response curves of platelet aggregation were performed in response to AA, ADP, collagen, epinephrine, TRAP-6 amide, and U46619.
Aggregometry was also performed on PRP incubated for 30 minutes with 1 µM MRS2500 (P2Y1 inhibitor) or 100 nM cangrelor (P2Y12 inhibitor) with
ADP as the agonist. For experiments with inhibitors, the maximal response (Rmax) was also calculated. EC50 and Rmax values were compared by one-
way analysis of variance (ANOVA) followed by Tukey’s HSD post hoc tests where appropriate. p-Values reported were adjusted to account for family-
wise error rate using Bonferroni corrections.
ap< 0.01 vs. baseline.
Fig. 3 The effect of hypoxia on platelet activation pathways. Dose–response curves of platelet aggregation in response to (A) arachidonic acid
(AA), (B) adenosine diphosphate (ADP), (C) collagen, (D) epinephrine, (E) thrombin receptor-activating peptide (TRAP)-6 amide and (F) U46619.
Data are mean percentage aggregation  standard error of the mean (SEM), and best ﬁt curves optimised to these mean values. EC50s were
compared by one-way analysis of variance (ANOVA) followed by Tukey’s HSD post hoc tests where appropriate. p-Values reported were adjusted
to account for family-wise error rate using Bonferroni corrections. p< 0.01 vs. baseline.
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clinical relevance of isolated, increased P2Y1 activity is unclear
since overall sensitivity to ADP was unaltered (►Fig. 3B,
►Table 2). Nonetheless, increased P2Y1 receptor activity has
beenpostulated to contribute to P2Y12 inhibitor resistance,
37,38
although evidence for this is lacking and to our knowledge no
study has investigated the impact of hypoxia on P2Y12 inhibitor
resistance.
An alternative explanation for the change in Rmax with
cangrelor is an increase in P2Y12 expression at altitude. Inter-
estingly, a recent whole blood microarray study showed a
twofold increase in P2Y12 expression in well acclimatised
sojourners at high altitude.39Theseﬁndingswere not validated
in isolated platelets or by quantitative polymerase chain reac-
tion. With either an increase in P2Y1 or P2Y12 expression, a
change in sensitivity to ADP might be expected in the absence
of inhibitors. However, as we detected no change in sensitivity
to ADP, we propose that our ﬁnding of increased basal VASP
phosphorylation is a compensatory mechanism that is also
activated by hypoxia. Together with a lack of change in maxi-
mum phosphorylation induced by iloprost (►Fig. 5B) and a
reduction in the percentage increase in phosphorylation
induced by iloprost (►Fig. 5C), this suggests that the basal
ratio of VASP:VASP-P is altered by hypoxia. Although we did
not observe reduced P2Y12 activity in response to ADP
(►Fig. 5A, C), we only studied a single high concentration of
ADP (5 µM), a concentration which induces near-maximal
aggregation (►Fig. 3B). It may be that lower concentrations
of ADP are unable to overcome increased basal VASP phos-
phorylation. If this is the case, it could represent a compensa-
tory response to increased P2Y1 receptor activity or P2Y12
expression, the explanations proposed for the reduction in
cangrelor efﬁcacy. VASP-P is regulated by several mediators
that are altered in hypoxic conditions. For example, exhaled
nitric oxide (NO) levels increased over 48 hours in healthy
subjects exposed acutely to 4,559m,40while raised circulating
cyclic guanosinemonophosphate (cGMP) levelsandNOmetab-
olites (nitrite and nitrate) were reported following gradual
ascent to 5,200m.41NO inhibits platelet aggregation, at least in
part via cGMP-mediated VASP phosphorylation as platelet
adhesion to injured vessel walls could not be inhibited by NO
in VASP-deﬁcient mice.42 Interestingly, recent work demon-
strated that nitrite led to VASP phosphorylation in isolated
platelets in the presence of deoxygenated red blood cells.43
Thus, either increasedNOsynthaseor nitrite reductase activity
could explain our ﬁnding of increased basal VASP phosphory-
lation at altitude.44►Fig. 6 summarises the proposed changes
to purinergic signalling induced by hypoxia; however, this
model will require further investigation to conﬁrm its validity.
Kiouptsi et al examined the effects of brief exposure
(30minutes) of washed human platelets to extreme andmod-
erate hypoxia (1 and 8% oxygen, respectively) on ex vivo
expression of activated αIIbβ3 (a key integrin in platelet aggre-
gation45) andaggregation. They reportedthatplateletsexposed
to extreme hypoxia had reduced expression of activated αIIbβ3
in response to ADP stimulation.46 Our proposed model of
hypoxia-induced alterations to purinergic signalling may offer
amechanistic explanation to theseﬁndings since an increase in
VASP phosphorylation would attenuate P2Y12 activity and
reduce ADP-induced activation of αIIbβ3.
47–49 Kiouptsi et al
also demonstrated that brief, extreme hypoxic exposure (1%
oxygen, 30minutes) reduced aggregation of hypoxic washed
platelets in response to TRAP-6. However, sensitivity of PRP to
TRAP-6 amide was unchanged.46 Our data did not show any
Fig. 4 The effect of hypoxia on adenosine diphosphate (ADP)-induced
platelet aggregation in the presence of ﬁxed doses of inhibitors.
Platelet-rich plasma (PRP) was incubated for 30 minutes with (A) 1 µM
MRS2500 (P2Y1 inhibitor) or (B) 100 nM cangrelor (P2Y12 inhibitor).
Data are mean percentage aggregation  standard error of the mean
(SEM), and best ﬁt curves optimised to these mean values. EC50 and
Rmax values were compared by one-way analysis of variance (ANOVA)
followed by Tukey’s HSD post hoc tests where appropriate. p-Values
reported were adjusted to account for family-wise error rate using
Bonferroni corrections. p< 0.01 vs. baseline.
Fig. 5 The effect of hypoxia on platelet vasodilator-stimulated
phosphoprotein (VASP) phosphorylation. Platelet-rich plasma (PRP)
was incubated for 6 minutes with phosphate-buffered saline (PBS),
iloprost or adenosine diphosphate (ADP) þ Iloprost before addition of
VASPFix. Flow cytometry was used to identify the ﬂuorescein iso-
thiocyanate (FITC) median ﬂuorescence (MF), reﬂecting the degree of
VASP phosphorylation. (A) Raw FITC MF for each condition at each
time point. Data are mean FITC MF standard error of the mean
(SEM). Data were compared by paired t-tests with p-values adjusted by
Bonferroni correction. (B) Percentage increase in FITC MF induced by
addition of iloprost. (C) Percentage decrease induced by ADP addi-
tion. (B, C) Individual data points are represented by semi-translucent
circles with box plots superimposed. Data were compared by paired t-
tests. p< 0.01, p< 0.001.
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difference in TRAP-6 sensitivity on day 6 (►Fig. 3E), but
reduced sensitivity was observed after a longer duration of
hypoxia. It couldbe thathypoxia-inducedchanges in sensitivity
to TRAP-6 amide evolve over time, and only after 11 days was
the effect on platelets pronounced enough to be seen in PRP.
Interestingly, transcription of the receptor for TRAP-6 amide,
protease-activated receptor 1, has also previously been shown
to be down-regulated in hypoxic cancer cells,50 but this has not
been investigated inplatelets andwould be an interesting topic
for further research.
This study has several limitations. First, it is difﬁcult to
predict the clinical relevance of subtle changes to signalling
when overall sensitivity to the agonist is not altered. Addi-
tionally, our study only examined the purinergic pathways in
detail, and it is possible that other subtle differences exist in
other signalling pathways. Finally, our study had a slight
gender imbalance, and sex has been shown to affect platelet
aggregation and purinergic signalling,51 implying our results
may be more relevant to women than men.
Detailed investigation of purinergic signalling provided
evidence of increased VASP phosphorylation and impaired
inhibition of aggregation by a P2Y12 antagonist. We did not,
however, ﬁnd evidence of increased sensitivity to any platelet
agonists despite the substantial evidence of hypoxia-induced
platelet hyper-reactivity in the literature. However, the
observed changes in aggregation in response to an ADP
antagonist are of potential therapeutic signiﬁcance to high-
altitude sojourners and hypoxic sea-level patients prescribed
platelet inhibitors and warrant further investigation.
What is known about this topic?
• Exposure to hypobaric hypoxia is thought to induce a
thrombogenic phenotype,with increased riskof stroke
in those residing at high altitude.
• The platelet proteome is altered by hypoxia and previ-
ous work has suggested platelet sensitivity to ADP is
increased at altitude.
What does this paper add?
• Using optimul aggregometry, we show no signiﬁcant
changes in the dose–response of several platelet
receptor agonists.
• Hypoxia suppressed the extent to which cangrelor
inhibited platelet aggregation to ADP, a ﬁnding with
potential implications for hypoxic patients taking
platelet inhibitors.
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